Search Results
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed AnTenGager™,
More news about: Antengene Corporation Limited
Dec 16, 2025, 07:20 ET Trust Your Gut--USANA's Probiotic Earns ConsumerLab.com Seal of Approval
probiotic strains, known for supporting healthy digestion, natural immune defenses, and a balanced microbiome.*Bifidobacterium BB-12® – A clinically studied strain that helps maintain digestive comfort, supports beneficial gut flora, and aids nutrient metabolism.*Survivability
More news about: USANA
Dec 15, 2025, 20:45 ET Justin Rutledge Joins First Horizon Bank as Charlotte Market President
Horizon, beginning his career at BB&T as a Management Associate and most recently serving as the Charlotte Market President for Truist. Over the course of his career, he has held roles in Mortgage, Commercial Banking, Middle Market and previously served as BB&T/Truist Market President for the Fort
More news about: First Horizon Bank
Dec 15, 2025, 08:00 ET Pele luminosa e firme na estação mais quente: tecnologias estéticas liberadas para o sol
mais de 20 anos de atuação no mercado, o Grupo MedSystems conta com mais de 40 equipamentos e produtos tecnológicos de ponta, como a linha Ultraformer, BB Laser Lavieen e Quanta System. O compromisso do Grupo MedSystems é fornecer soluções que geram prosperidade e transformam vidas, consolidando-se como
More news about: Medsystems
Dec 11, 2025, 00:50 ET 新橋生物公佈 Ragistomig 1期劑量拓展研究數據：療效可比，安全性顯著提升
Ragistomig 是一種 4-1BB X PD-L1 雙特異性抗體，旨在治療使用檢查點抑制劑後復發或難治的晚期或轉移性實體瘤患者。作為癌症治療的支柱，檢查點抑制劑市場規模達數十億美元，但廣泛存在的耐藥性限制了其療效。研究目標已達成：對於既往使用過抗PD-(L)1等免疫療法後難治或復發的患者，新的每6週一次（Q6W） 延長給藥間隔方案不僅展現出了令人鼓舞的抗腫瘤療效和免疫學數據，相較於此前每2週一次（Q2W）的方案，安全性也顯著改善。本次發佈的海報展示了包含CD8+ 細胞增殖和記憶 T 細胞活化在內的積極免疫學數據。
More news about: 新橋生物
Dec 10, 2025, 08:52 ET Dose-Intensive CK0804 Regimen Reduces Spleen Volume and Transfusion Needs in JAK Inhibitor-Resistant/ Suboptimal Myelofibrosis with Thrombocytopenia
was observed in 78% of patients (9 of 11).Biomarker profile: Clinical responses correlated with reductions in FGF, sCD40L, PDGF‑AA, and PDGF‑AA/BB.Thrombocytopenic subgroup: All three thrombocytopenic patients tolerated the intensive CK0804 regimen; all had a 100% reduction in symptom
More news about: Cellenkos, Inc.
Dec 09, 2025, 08:08 ET Carner Corporate Finance wins Finland's Financial Advisor of the year at 2025 Mergermarket Europe Awards: B&B Communications
content:https://www.prnewswire.com/news-releases/carner-corporate-finance-wins-finlands-financial-advisor-of-the-year-at-2025-mergermarket-europe-awards-bb-communications-302636583.htmlSOURCE
More news about: B&B Communications
Dec 09, 2025, 08:00 ET Verismo Therapeutics Shares Positive Preclinical Data at ASH 2025 Comparing SynKIR™-310 With Conventional CAR T
Using NK cell derived KIR and DAP12 split-signaling provides a novel paired activation that is independent from CD3 signaling, and does not require 41BB/CD28 co-stimulation KIR-CAR enables sustained chimeric receptor expression with improved long-term CAR T cell function and decreased T cell exhaustion.
More news about: Verismo Therapeutics
Dec 08, 2025, 10:00 ET Splitero, Funds Managed by Blue Owl, and Antarctica Capital Close $283.3 Million Home Equity Investment Inaugural Securitization
class A-1 rated A (low) (sf), $48 million of mezzanine class A-2 securities rated BBB (low) (sf), $11.5 million of subordinate class B-1 securities rated BB (high) (sf), and $28.3 million of subordinate class B-2 securities rated B (sf) (retained), all rated by Morningstar DBRS. The securitization received
More news about: Splitero
Dec 07, 2025, 21:00 ET Median PFS Trending Beyond One Year: Leads Biolabs' LBL-034 Showcases Breakthrough Clinical Data in Oral Presentation at the 2025 ASH Annual Meeting
We have also developed multiple proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical
More news about: Leads Biolabs
Dec 05, 2025, 05:19 ET ZINZINO AB (PUBL.): Zinzino AB changes Certified Adviser to Tapper Partners AB
https://mb.cision.com/Public/10976/4277666/bb8c1525a8a99fc3.pdf2512 Pressrelease
More news about: Zinzino
Dec 04, 2025, 08:13 ET 新橋生物宣佈將在ESMO-IO大會上公佈Ragistomig擴展性1期臨床數據
Ragistomig是一款4-1BB × PD-L1雙特異性抗體，旨在治療使用檢查點抑制劑後病情復發或效果欠佳的患者。作為百億美元級藥物，檢查點抑制劑雖應用廣泛，但時常面臨著耐藥問題Ragistomig的1期研究已達目標：延長至每六週一次的（Q6W）新給藥間隔方案在對PD-L1抑制劑無應答的患者中表現出強效抗腫瘤活性，且安全性特徵更優包含CD8+細胞增殖和記憶T細胞活化等免疫學數據的中期結果，預計將於格林威治時間2025年12月10日下午5點30分在歐洲腫瘤內科學會免疫腫瘤學大會（ESMO-IO）上以海報形式公佈
More news about: 新橋生物
Dec 03, 2025, 03:30 ET RIMAN acelera el crecimiento en México con la introducción de ICD Beauty
formulaciones innovadoras y respaldadas por la ciencia a la categoría de maquillaje.La línea incluye:ICD Beauty Sheer Glow BBICD Beauty Luminous Glow CushionICD Beauty Lip Tint (semi mate y terciopelo mate)ICD Beauty Glow Up Lip
More news about: RIMAN Inc.
Dec 02, 2025, 09:21 ET Octane Completes $219 Million Asset-Backed Securitization
five classes of fixed-rate notes: Class A, Class B, Class C, Class D, and Class E, which Standard & Poor's (S&P)* rated as AAA, AA, A, BBB, and BB+ respectively, in a private offering pursuant to Rule 144A under the Securities Act of 1933, as amended. ATLAS SP Securities acted as lead manager and
More news about: Octane
Dec 02, 2025, 04:00 ET Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).Antengene has also developed AnTenGager™,
More news about: Antengene Corporation Limited
Nov 26, 2025, 08:00 ET Verão à vista: tecnologias ajudam a conquistar a barriga dos sonhos
mais de 20 anos de atuação no mercado, o Grupo MedSystems conta com mais de 40 equipamentos e produtos tecnológicos de ponta, como a linha Ultraformer, BB Laser Lavieen e Quanta System. O compromisso do Grupo MedSystems é fornecer soluções que geram prosperidade e transformam vidas, consolidando-se como
More news about: Grupo MedSystems
Nov 24, 2025, 17:00 ET Tuya Reports Third Quarter 2025 Unaudited Financial Results
https://register-conf.media-server.com/register/BI86c04c19c52a48c6bb64d46104c02dffA live and archived webcast of the conference call will also be available at the Company's investor relations
More news about: Tuya Inc.
Nov 24, 2025, 16:06 ET AllianceBernstein National Municipal Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
16.51 %BB
More news about: AllianceBernstein National Municipal Income Fund, Inc.
Nov 24, 2025, 16:06 ET AllianceBernstein Global High Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
14.60 %BB
More news about: AllianceBernstein Global High Income Fund, Inc.
Nov 24, 2025, 11:38 ET Alfa Laval Capital Markets Day 2025 - strengthening growth and profitability ambitions
https://mb.cision.com/Public/905/4271304/9bb3443749345a2c.pdfAlfa Laval Capital
More news about: Alfa Laval
Nov 22, 2025, 00:46 ET Republic of Colombia Announces the Expiration of the Tender Offer for its Non-U.S. Dollar Bonds and Final Results of Tender Offer
2033CUSIP: 195325BB0ISIN: US195325BB02U.S.$201,047,840.00
More news about: Republic of Colombia
Nov 21, 2025, 16:00 ET Ziegler Closes $80,000,000 Financing for Brazos Presbyterian Homes
Brazos Presbyterian Homes (BPH). The Series 2025 Bonds were issued through the New Hope Cultural Education Facilities Finance Authority and are rated 'BB+' (Stable) by Fitch.
More news about: Ziegler
Nov 20, 2025, 00:04 ET Republic of Colombia Announces the Expiration of the Tender Offer for its U.S. Dollar Bonds
CUSIP: 195325BB0 ISIN: US195325BB02
More news about: Republic of Colombia
Nov 19, 2025, 21:56 ET Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
mid/late-stage clinical programs, including ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), ATG-037 (oral CD73 small molecule inhibitor), and ATG-101 (PD-L1/4-1BB bispecific antibody). The company will also share the latest progress on ATG-125 (B7H3 x PD-L1 bispecific ADC): A B7H3
More news about: Antengene Corporation Limited
Nov 19, 2025, 09:05 ET BroadbandOne® Partners with Ripple Broadband to Deliver Next-Gen Wireless Internet to Pensacola
BroadbandOne BroadbandOne (BB1) is an innovative wireless network operator and value added partner deploying carrier grade IP connectivity services to enterprises in Tier 2 and 3 and rural markets in the U.S. BB1 is one of the nation's largest holders of 5G spectrum in
More news about: BroadbandOne